Professor Paul Workman is Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research (ICR) in London and is also a Group Leader in Signal Transduction and Molecular Pharmacology at ICR. From 2014-2021 he served as Chief Executive and President of the ICR and from 1997-2016 he was Director the ICR’s CRUK Cancer Therapeutics Unit. Paul previously held senior research positions at the MRC Oncology Unit, Cambridge University; CRUK Beatson Laboratories, Glasgow University; and Zeneca Pharmaceuticals, Alderley Park. Paul is an international leader in the field of cancer drug discovery and chemical biology, known especially for his work on the discovery of inhibitors of protein kinases, PI3 kinases, HSP90, HSP70 and the HSF1 and integrated stress response pathways.  He has been instrumental in the discovery of multiple molecular therapeutic agents that have entered clinical trials, including the approved drugs gefitinib and capivasertib. As a scientific entrepreneur, Paul has been involved in multiple biotech companies, including as Scientific Founder of Chroma Therapeutics and Piramed Pharma (acquired by Roche). An enthusiast for high-quality chemical probes in biomedical research, Paul is Executive Director of the non-profit Chemical Probes Portal. Paul has received multiple awards and fellowships and is a Fellow of the Royal Society (the UK’s academy of science).